GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

Jul. 28, 2022 10:35 AM ETGeoVax Labs, Inc. (GOVX)By: Dulan Lokuwithana, SA News Editor

Ebola virus disease concept. Professional doctor or lab technician in medical blue glove holding blood sample with Zaire ebolavirus testing on tube, medical and health care

Pornpak Khunatorn/iStock via Getty Images

  • The shares of clinical-stage biotech GeoVax Labs (NASDAQ:GOVX) added ~16% in the morning hours Thursday after the company announced a peer-reviewed publication of an animal efficacy study on the company’s experimental vaccine

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.